

## A Comprehensive Approach to Increase Adult Tobacco Cessation

Brenna VanFrank, MD, MSPH; Letitia Presley-Cantrell, PhD

**Quitting smoking** is one of the most important changes individuals can make to improve their health. The US Surgeon General concluded in 2020 that smoking cessation reduces the risk for all-cause mortality, cardiovascular diseases, chronic obstructive pulmonary disease, adverse reproductive health outcomes, and 12 types of cancer.<sup>1</sup> Although considerable progress has been made in the US in reducing smoking over the past half century, there is still work to be done: it is estimated that 34 million US adults smoke cigarettes,<sup>2</sup> more than 480 000 die annually from smoking or tobacco smoke exposure, and more than 16 million are living with a smoking-related illness.<sup>3</sup>

When it comes to addressing the smoking epidemic, what works is well known: evidence-based interventions at the individual, health system, and population levels have been scientifically shown to prevent and reduce smoking.<sup>1,3</sup> Yet while significant gains have been made by the public health community in advancing prevention strategies, cessation remains a challenge. In a nationally representative survey of 33 672 adults, 68.0% of those who currently smoke reported wanting to quit and 55.4% reported trying to do so.<sup>1</sup> However, only 31.2% of adults who smoke used evidence-based treatment when trying to quit, and only 7.4% successfully quit smoking in a given year.<sup>1</sup> The situation is compounded by marked disparities that persist in both smoking prevalence and cessation-related measures across population groups.<sup>1</sup>

As a nation, the US can do better, but it will take a comprehensive, interdisciplinary approach. One key opportunity is for the public health and health care sectors to join forces to reduce the significant burden of tobacco-related morbidity and mortality. The mobilization of the health care sector is critical, given that tobacco dependence is a chronic, relapsing substance use disorder that often requires multiple interventions and long-term support for successful recovery.<sup>4,5</sup>

In this issue of *JAMA*, the US Preventive Services Task Force (USPSTF) has updated its recommendations<sup>6</sup> and supporting evidence review<sup>7</sup> on the screening and treatment of tobacco use and has reaffirmed the importance of clinician action in the prevention of tobacco-related disease. The USPSTF has issued an A recommendation for screening for tobacco use and delivery of advice to quit for all adults, including pregnant persons.<sup>6</sup> The USPSTF has further recommended that clinicians provide behavioral interventions and US Food and Drug Administration (FDA)-approved medications to nonpregnant adults to aid in quitting (A recommendation).<sup>6</sup> These recommendations are consistent with those of the US Surgeon

General, who has concluded that a combination of behavioral counseling and FDA-approved medication can increase an individual's likelihood of successfully quitting.<sup>1</sup>

For pregnant persons who use tobacco, the USPSTF has issued an A recommendation to provide behavioral interventions to aid in tobacco cessation.<sup>6</sup> Pharmacotherapy for pregnant persons remains an I statement, given that the evidence for the balance of benefit to harm for these interventions remains insufficient with few studies available.<sup>6</sup>

Behavioral counseling and FDA-approved pharmacotherapy are also the mainstay in clinical practice guidelines.<sup>5,8</sup> However, despite these prominent endorsements of efficacy and safety, less than 5% of US adults who try to quit smoking use this combination of treatments.<sup>1</sup>

While screening and treatment have been, and continue to be, essential to the clinical prevention of tobacco-related disease, the evidence for cessation therapies has continued to evolve. Evidence-based behavioral interventions now include individual and group counseling, telephone counseling such as that received through state quitlines (1-800-QUIT-NOW), and web- and text-based interventions.<sup>1</sup> Approaches to pharmacotherapies have also evolved. For example, combining long- and short-acting nicotine replacement therapies has been found to be more effective than single forms of nicotine replacement therapy, and preloading (ie, starting medication in advance of a quit attempt) with nicotine patch may also increase successful cessation.<sup>1</sup> Available evidence related to electronic cigarettes (e-cigarettes) as a potential cessation tool has increased as well. Although it remains uncertain whether e-cigarettes, in general, can help people quit smoking, some research suggests that use of certain e-cigarettes containing nicotine or using them more frequently is associated with greater smoking cessation.<sup>1</sup> However, the long-term health effects of e-cigarette use remain largely unknown,<sup>9</sup> and the USPSTF has issued an I statement for insufficient evidence regarding the use of e-cigarettes for cessation.<sup>6</sup> No e-cigarette has been approved by the FDA as a cessation aid.

In treating tobacco use and dependence, primary care clinicians should not be expected to do the work alone. It is well established that cigarette smoking harms nearly every organ system and adversely affects a wide range of clinical outcomes.<sup>3</sup> Ensuring that individuals are provided with and connected to evidence-based treatment and support to quit is the responsibility of every care team in every specialty and in every setting, including ambulatory, inpatient, and behavioral health care.

Systems-level changes can make it easier for clinicians to give their patients the treatment they need. For example, team-based approaches to care, including chronic disease management models, can mitigate the burden of screening



Multimedia



Related articles [pages 265 and 280](#) and [JAMA Patient Page page 316](#)

and treatment delivery on any one individual.<sup>5</sup> Integrating screening and treatment into policies and clinical processes can help clinicians effectively deliver treatment, and establishing clinical protocols can routinize intervention.<sup>5</sup> Additionally, extending treatment with cessation services like quitlines, web interventions, and text interventions,<sup>1</sup> and through community-based health professionals such as pharmacists<sup>10</sup> and community health workers,<sup>11</sup> has potential to extend the reach and effectiveness of clinical interventions. Furthermore, delivery of clinical interventions can also be increased with the linkage of payment to cessation-related quality measures and the availability and dissemination of clinical practice guidelines.<sup>1</sup> Health care professionals and systems can approach these types of system-level changes through clinical quality improvement processes.<sup>12</sup> Such efforts can be enhanced when health systems work in partnership with public health entities (eg, state tobacco control programs) with experience integrating tobacco screening and treatment into care settings.<sup>13</sup>

In addition to treatment delivery and systems-based supports, health care professionals and systems can also support population-level strategies that not only increase smoking cessation but also prevent initiation of tobacco use. The evidence base is well established for such population-level strategies, including tobacco price increases, smoke-free policies, mass-media tobacco education campaigns, and access to cessation treatments.<sup>1,3</sup> In particular, enhanced access to and

utilization of cessation treatments can be accomplished, in part, by the provision of insurance coverage that comprehensively covers all evidence-based therapies, is barrier-free (eg, no treatment limits or prior authorizations), and is promoted to both enrollees and clinicians.<sup>1</sup> Health systems can support these population-level strategies and engage in proven tobacco control policy efforts by leveraging their own community health needs assessments and implementation plans.<sup>14</sup> Additionally, health care systems and the public health community can partner on community health improvement plans<sup>15</sup> to engage in multisector approaches to facilitate these population-level strategies.

Helping people recover from tobacco use and dependence requires the partnership of the public health community and health care professionals from all specialties and across disciplines to deliver comprehensive support through interventions at individual, system, and population levels. It is important that every patient is systematically and routinely screened for tobacco use, that everyone who uses tobacco has access to—and is provided with—quality, evidence-based cessation treatment, and that all people are provided the community and environmental supports they need to stay tobacco-free. These efforts must be applied comprehensively and equitably across communities to ensure that no one is left behind. Moving forward together, health care and public health can comprehensively support tobacco cessation and achieve greater health for all.

#### ARTICLE INFORMATION

**Author Affiliations:** Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.

**Corresponding Author:** Brenna VanFrank, MD, MSPH, Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy, NE, Atlanta, GA 30341 (bvanfrank@cdc.gov).

**Conflict of Interest Disclosures:** None reported.

**Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

#### REFERENCES

1. US Department of Health and Human Services. *Smoking Cessation: A Report of the Surgeon General*. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2020.
2. Cornelius ME, Wang TW, Jamal A, Loretan CG, Neff LJ. Tobacco product use among adults—United States, 2019. *MMWR Morb Mortal Wkly Rep*. 2020; 69(46):1736-1742. doi:10.15585/mmwr.mm6946a4
3. US Department of Health and Human Services. *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*. Centers for Disease Control and Prevention, National Center

for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.

4. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. American Psychiatric Association; 2013.
5. US Department of Health and Human Services. *Treating Tobacco Use and Dependence: 2008 Update: Clinical Practice Guideline*. US Dept of Health and Human Services; May 2008.
6. US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. *JAMA*. Published January 19, 2020. doi:10.1001/jama.2020.25019
7. Patnode CD, Henderson JT, Coppola EL, Melnikow J, Durbin S, Thomas RG. Interventions for tobacco cessation in adults, including pregnant persons: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA*. Published January 19, 2020. doi:10.1001/jama.2020.23541
8. Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*. 2018;72(25):3332-3365. doi:10.1016/j.jacc.2018.10.027
9. National Academies of Sciences, Engineering, and Medicine. *Public Health Consequences of E-Cigarettes*. National Academies Press; 2018.
10. Practice Guidance for Expanding Pharmacy-Based Tobacco Cessation Services

Within the Appointment-Based Model. American Pharmacists Association. Published December 2018. Accessed December 8, 2020. [https://www.pharmacist.com/sites/default/files/files/Practice\\_Guidance\\_Tobacco\\_Cessation.pdf](https://www.pharmacist.com/sites/default/files/files/Practice_Guidance_Tobacco_Cessation.pdf)

11. Andrews JO, Mueller M, Dooley M, Newman SD, Magwood GS, Tingen MS. Effect of a smoking cessation intervention for women in subsidized neighborhoods: a randomized controlled trial. *Prev Med*. 2016;90:170-176. doi:10.1016/j.ypmed.2016.07.008
12. Centers for Disease Control and Prevention. *Tobacco Cessation Change Package*. Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2020.
13. Centers for Disease Control and Prevention. *Best Practices User Guide: Cessation in Tobacco Prevention and Control*. US Dept of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2020.
14. Community health needs assessments. Association of State and Territorial Health Officials. Accessed November 30, 2020. <https://www.astho.org/Programs/Access/Community-Health-Needs-Assessments/>
15. Community health assessment & health improvement planning. Centers for Disease Control and Prevention. Updated August 13, 2018. Accessed November 30, 2020. <https://www.cdc.gov/publichealthgateway/cha/index.html>